Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Statement re September Factsheet

20 Oct 2015 07:00

RNS Number : 7360C
BlueCrest AllBlue Fund Ltd
20 October 2015
 



FOR IMMEDIATE RELEASE

 

20 October 2015

 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - SEPTEMBER 2015

"A solid performance against difficult markets"

 

BlueCrest AllBlue Fund Limited (BCAB) rose by 0.3% in September, a solid performance against a backdrop of difficult markets, bringing the gain for the year to date to 2.9% (Sterling Class NAV). The rolling 12 month return remained level at 3.8% and volatility was stable, at 3.2%.

 

Markets were nervous and choppy as economic data remained generally disappointing, particularly from China. Emerging markets continued to feel the strain and the MSCI Emerging Markets index finished September down 17% on a year to date basis. Credit markets also suffered and exhibited some illiquidity, particularly in high yield. The US Federal Reserve keeping rates unchanged did nothing to settle investors' stomachs.

 

"Strongest performance came from BlueTrend 2x"

 

As in August, five of the seven underlying strategies generated positive performance. BlueCrest Multi Strategy Credit and BlueCrest Quantitative Equity detracted once again, albeit only modestly.

 

The strongest performance came from BlueTrend 2x, which rose by over 4.5% on the month. Although only three of BlueTrend's seven strategies produced positive performance, the four detracting strategies did little to dent to strong gains coming from long positioning in bonds, an orientation which was maintained by the model for the entire month. Strong performance was also seen from the short term interest rates sector. Positioning in equities and commodities was maintained net short. Overall risk levels increased slightly during the month.

 

Despite the turmoil in emerging markets, BlueCrest Emerging Markets Fund eked out a small gain. BlueCrest Multi Strategy Credit was the worst performing fund in September at -0.6% on the month. Gains were seen in volatility trading and convertible bond arbitrage with losses in long/short strategies. High yield positioning was largely flat despite illiquidity in the cash bond market seeing some sharp price falls. The risk exposure in the fund was already defensive entering September and there were further modest tactical risk reductions during the month.

 

BlueCrest Mercantile produced a small positive return as both the Trade Credit Opportunities and Bank Basel III strategies were positive. The former saw the Ukrainian sovereign CDS hedges triggered by default but the underlying trade finance positions pay out in full. The Bank Basel III strategy produced the majority of returns as emerging market mark-downs were offset by CDS hedge protection. Small losses were seen from some mining positions. A good pipeline of securitisations is being seen which are expected to become available by year end.

 

A small increase of 1.5% was made to the allocation to BlueCrest Equity Strategies for October at the expense of BlueTrend 2x and BlueCrest Capital International.

 

"The Company continued its buyback"

 

The Company continued its buyback activity during September, although selling pressure has subsequently abated. The discount remains reasonably stable, either side of 5%.

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRUKAVRVAARAAA
Date   Source Headline
29th Jul 20204:32 pmRNSNet Asset Value - Weekly Estimate
29th Jul 20202:17 pmRNS2019 Redemption Portfolio
29th Jul 20202:15 pmRNSNet Asset Value - Month End Final
21st Jul 20204:22 pmRNSNet Asset Value - Weekly Estimate
16th Jul 20202:44 pmRNSNet Asset Value - Weekly Estimate
8th Jul 20201:13 pmRNSNet Asset Value - Weekly Estimate
2nd Jul 20205:11 pmRNSProvision 4 of the UK Corporate Governance Code
2nd Jul 202010:03 amRNSNet Asset Value(s) - Weekly Estimate
26th Jun 20203:11 pmRNSHolding(s) in Company
24th Jun 20205:07 pmRNSNet Asset Value - Weekly Estimate
23rd Jun 20205:16 pmRNS2019 Redemption Portfolio
23rd Jun 20205:15 pmRNSNet Asset Value(s) - Month End Final
17th Jun 202012:46 pmRNSNet Asset Value(s) - Weekly Estimate
12th Jun 202011:27 amRNSNet Asset Value(s) - Weekly Estimate
4th Jun 20202:39 pmRNSNet Asset Value(s) - Weekly Estimate
28th May 20204:17 pmRNSNet Asset Value(s) - Month End Final
28th May 20204:08 pmRNS2019 Redemption Portfolio
28th May 20203:46 pmRNSNet Asset Value(s) - Weekly Estimate
21st May 20205:01 pmRNSNet Asset Value(s) - Weekly Estimate
15th May 20203:42 pmRNSNet Asset Value(s) - Weekly Estimate
6th May 20204:06 pmRNSNet Asset Value(s) - Weekly Estimate
5th May 20201:58 pmRNSDisclosure of rights attached to equity shares
5th May 20201:47 pmRNSDirector/PDMR Shareholding
4th May 20205:16 pmRNS2019 Redemption Portfolio
4th May 20204:41 pmRNSNet Asset Value(s) - Month End Final
1st May 202010:11 amRNSCorrection to Disclosure of Notifiable Interests
30th Apr 20203:39 pmRNSNet Asset Value(s) - Weekly Estimate
28th Apr 20206:31 pmRNSDirector/PDMR Shareholding
27th Apr 20207:00 amRNSNotice of AGM
27th Apr 20207:00 amRNSAnnual Financial Report
23rd Apr 20204:53 pmRNSNet Asset Value(s) - Weekly Estimate
17th Apr 20203:39 pmRNSNet Asset Value(s) - Weekly Estimate
17th Apr 20209:15 amRNSNet Asset Value(s) - Weekly Estimate
14th Apr 20205:12 pmRNSCash Exit Payment
9th Apr 20205:39 pmRNSNet Asset Value(s) - Monthly Estimate
2nd Apr 20202:53 pmRNS2019 Redemption Portfolio
2nd Apr 20202:41 pmRNSNet Asset Value(s) - Weekly Estimate
26th Mar 20205:05 pmRNSNet Asset Value(s) - Month End Final
26th Mar 20204:53 pmRNSNet Asset Value(s) - Weekly Estimate
19th Mar 20201:31 pmRNSNet Asset Value(s)- Weekly Estimate
13th Mar 202011:41 amRNSHolding(s) in Company
12th Mar 20209:46 amRNSNet Asset Value(s) - Weekly Estimate
9th Mar 202012:20 pmRNSNet Asset Value(s) - Weekly Estimate
3rd Mar 20205:02 pmRNS2019 Redemption Portfolio
2nd Mar 20205:29 pmRNSNet Asset Value(s) - Month End Final
26th Feb 20203:33 pmRNSNet Asset Value(s) - Weekly Estimate
20th Feb 20202:05 pmRNSResult of EGM
19th Feb 20203:50 pmRNSNet Asset Value(s) - Weekly Estimate
12th Feb 20205:13 pmRNSNet Asset Value(s) - Weekly Estimate
7th Feb 20209:17 amRNS2019 Redemption Portfolio

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.